Related Experiment Video
Updated: Jun 28, 2026
07:00
Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis
Published on: October 13, 2016
[Dementia in amyotrophic lateral sclerosis].
Ole Gredal1, Karin Nielsen, Troels Tarp
1RehabiliteringsCenter for Muskelsvind, Bernstorffsvej 20, DK-2900 Hellerup. gredal@dadlnet.dk
Ugeskrift for Laeger
|October 23, 2008
Summary
Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) often co-occur, complicating patient care. This study details monitoring cognitive changes to enhance ALS patient rehabilitation and palliative care.
Area of Science:
- Neurodegenerative diseases
- Neurology
- Clinical neuroscience
Context:
- Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) are distinct yet frequently comorbid neurodegenerative disorders.
- The simultaneous presentation of ALS and FTD presents significant challenges for patient management and family support.
- Understanding the interplay between these conditions is crucial for effective clinical practice.
Purpose:
- To highlight the clinical complexities arising from the co-occurrence of ALS and FTD.
- To introduce a monitoring framework for cognitive and personal changes in ALS patients with potential FTD overlap.
- To provide strategies for improving rehabilitation and palliative care outcomes.
Summary:
- Clinical observations indicate a significant connection between Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.
- Simultaneous manifestation of these diseases complicates disease trajectory and necessitates tailored management approaches.
- A systematic method for tracking cognitive and behavioral alterations in ALS patients is proposed to guide care.
Impact:
- Improved diagnostic and prognostic accuracy for patients with overlapping ALS and FTD symptoms.
- Enhanced patient-centered care through personalized rehabilitation and palliative strategies.
- Better support systems for families affected by these complex neurodegenerative conditions.
More Related Videos
Related Concept Videos
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...